Condition
Mesothelin-positive Advanced Malignant Solid Tumors
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (3)
Trial Status
Recruiting2
Unknown1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06756035Phase 1Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT07010523Not ApplicableRecruitingPrimary
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
NCT05848999Phase 1UnknownPrimary
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
NCT05783089Phase 1Not Yet RecruitingPrimary
MSLN-targeted CAR-T Cells in Solid Tumors.
Showing all 4 trials